Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HCK | P08631 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29861748 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP3A4TSHRCLK4HSD17B10 | |
| SCHEMBL23326744 | 0.81 | HSD17B10 (0.33) | CYP1A2CYP3A4TSHRCLK4HSD17B10 | |
| SCHEMBL29861403 | 0.81 | HSD17B10 (0.33) | CYP1A2CYP3A4TSHRCLK4HSD17B10 | |
| SCHEMBL25396743 | 0.78 | ALDH1A1 (0.38) | CYP1A2TSHRHSD17B10ALDH1A1MAPT | |
| SCHEMBL23326861 | 0.77 | PIK3CA (0.36) | HSD17B10ESR1ESRRAESR2ALDH1A1 | |
| SCHEMBL29861520 | 0.77 | PIK3CA (0.36) | HSD17B10ESR1ESRRAESR2ALDH1A1 | |
| SCHEMBL23345379 | 0.73 | SOS1 (0.38) | SOS1 | |
| Hydrochloric Acid SCHEMBL29910321 | 0.72 | SOS1 (0.38) | SOS1 | |
| Hydrochloric Acid SCHEMBL23326864 | 0.72 | SOS1 (0.38) | SOS1 | |
| SCHEMBL29918606 | 0.70 | ESR2 (0.32) | ESR2SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-20250186434-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| WO-2023178130-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-116669738-A | Pyrimidopyridone derivative as SOS1 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116425742-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20220324862-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED | 2022-10-13 | — | — | US | disclosed |
| WO-2022212531-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-4055017-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022170802-A1 | PYRIMIDO-PYRIDONE DERIVATIVE AS SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| WO-2022170802-A1 | PYRIMIDO-PYRIDONE DERIVATIVE AS SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| CN-114901662-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190868-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | CYP1A2 3183/4885CYP3A4 3709/4885TSHR 3387/4885 |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | CYP1A2 1997/4885CYP3A4 3216/4885TSHR 2547/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CYP1A2 2086/4885CYP3A4 2915/4885TSHR 2669/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CYP1A2 2086/4885CYP3A4 2915/4885TSHR 2669/4885 |
| US-20220324862-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | RSU1, SOST, CCNA1 | CYP1A2 1271/4885CYP3A4 1147/4885TSHR 1615/4885 |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | SOST, SOS1, SOS2 | CYP1A2 2086/4885CYP3A4 2915/4885TSHR 2669/4885 |
| US-20250186434-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, CUL1, SOS2 | CYP1A2 3383/4885CYP3A4 3826/4885TSHR 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.